platoseedplatoseed
Platform for breakthrough mental health research and treatment
Osmind is the premier platform for clinicians and researchers advancing new life-saving mental health treatments. Today, mental health disorders are one of the leading causes of death worldwide, especially among young adults, and are tied to shortening lifespans. While there have been developments in new psychiatric medications since the first FDA approval in 1954, today there is a growing movement among clinicians, patients, and researchers who are recognizing the need to accelerate new science. The Osmind treatment platform is the first and only solution that solves specific challenges faced by neuropsychiatric clinics, spanning general psychiatry and interventional psychiatry (transcranial magnetic stimulation, ketamine, SPRAVATO®, psychedelic medicine, electroconvulsive therapy). The core electronic health record (EHR) technology is precisely developed for interventional treatment workflows and designed to support a strong therapeutic alliance, including journaling tools and assistance with health plan reimbursement, which is a significant access hurdle for millions of patients. Research from our platform is already helping to set new standards for mental health interventions. For example, in the largest published real-world analysis of ketamine infusion therapy for depression, we teamed up with Stanford University School of Medicine to share findings in the Journal of Affective Disorders (March 2022). We have multiple ongoing research studies leveraging our proprietary real-world data, including an even larger ketamine analysis leveraging machine learning to predict treatment outcomes. Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists. We are backed by top investors including DFJ Growth, General Catalyst, Future Ventures, Tiger Global, and Y Combinator.
Osmind provides a psychiatry-focused platform offering an AI-powered EHR, billing/RCM, and network services designed for interventional psychiatry modalities like Spravato and TMS. It supports a large network of practices with payer contracts, early access to therapies, and operational playbooks to scale specialized psychiatry care.
Osmind combines an AI-powered EHR with billing, prior authorization, eligibility verification, and patient engagement tailored for interventional psychiatry. It includes SPRAVATO REMS integration, e-prescribing, automated workflows for copays and intake, and access to negotiated payer rates, group purchasing, and practice templates. The platform enables launching new modalities, supports research and life sciences integrations, and connects a network of 1,000+ practices to leverage scale and negotiated discounts.
Who it’s for: Independent psychiatry practices and clinics delivering interventional psychiatry treatments (e.g., Spravato, TMS) seeking integrated EHR, billing, payer contracts, and access to a large care network
Public pricing pages; multiple product bundles; claims of 1,000+ practices in network; emphasis on growth, bundled services, and performance-based pricing
Lucia Huang is co-founder and CEO of Osmind, which provides software and data for precision mental health. Previously, she ran business and operations at Verge Genomics (S15) and helped scale the company from seed to A. She started her career in healthcare investment banking and investing. Lucia graduated with an MBA from Stanford and a B.S. Chemistry degree from Yale, where she first began to explore her passion for healthcare. She is a proud Californian and loves surfing, cycling, and hiking.
Clinical-stage AI neuroengineering platform
A modern-day mental healthcare company for global workforces.
